Oncternal Therapeutics Inc

ONCT NASDAQ
4.230
+0.070
+1.68%
Closed 16:00 08/16 EDT
Open
4.630
Prev Close
4.160
High
4.650
Low
4.170
Volume
7.26K
Avg Vol (3M)
143.12K
52 Week High
179.20
52 Week Low
3.430
% Turnover
0.05%
Market Cap
65.08M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Oncternal Therapeutics Inc ONCT stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Oncternal Therapeutics, Inc., formerly GTX, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of product candidates for the treatment of cancers. Its pipeline includes cirmtuzumab, TK-216 and chimeric antigen receptor T-cell (CAR-T). Its cirmtuzumab product candidate is an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) monoclonal antibody. Cirmtuzumab is in a Phase-I/II clinical trial in combination with ibrutinib for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). TK216 is a small-molecule compound designed to inhibit the biological activity of E26 transformation-specific (ETS) oncoproteins. TK216 is being evaluated in combination with vincristine in a Phase-I clinical trial in patients with relapsed or refractory Ewing sarcoma. Its CAR-T product candidate targets ROR-1 and is in preclinical development as a treatment for hematologic cancers and solid tumors.
MORE >

Recently

Name
Price
%Change